Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(0.64)
# 3,865
Out of 4,868 analysts
46
Total ratings
22.22%
Success rate
-21.49%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Reiterates: Overweight | n/a | $21.31 | - | 2 | Jun 10, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $20.16 | - | 2 | Apr 23, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $5.85 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $3.01 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $9.43 | +37.96% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $3.03 | - | 2 | Mar 7, 2025 | |
| PRTA Prothena Corporation | Reiterates: Overweight | n/a | $5.75 | - | 1 | Feb 21, 2025 | |
| CRSP CRISPR Therapeutics AG | Reiterates: Neutral | n/a | $44.43 | - | 4 | Feb 19, 2025 | |
| INCY Incyte | Reiterates: Neutral | n/a | $68.27 | - | 6 | Jan 10, 2025 | |
| AGIO Agios Pharmaceuticals | Reiterates: Overweight | n/a | $35.46 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $4.80 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $96 | $29.32 | +227.42% | 4 | Sep 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $31.70 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $126.54 | +130.76% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $448.40 | -17.48% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.35 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.30 | - | 1 | May 30, 2017 |
Cidara Therapeutics
Jun 10, 2025
Reiterates: Overweight
Price Target: n/a
Current: $21.31
Upside: -
Summit Therapeutics
Apr 23, 2025
Reiterates: Overweight
Price Target: n/a
Current: $20.16
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.85
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.01
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $9.43
Upside: +37.96%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $3.03
Upside: -
Prothena Corporation
Feb 21, 2025
Reiterates: Overweight
Price Target: n/a
Current: $5.75
Upside: -
CRISPR Therapeutics AG
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $44.43
Upside: -
Incyte
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $68.27
Upside: -
Agios Pharmaceuticals
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $35.46
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $4.80
Upside: -
Sep 18, 2024
Reiterates: Overweight
Price Target: $96
Current: $29.32
Upside: +227.42%
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $31.70
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $126.54
Upside: +130.76%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $448.40
Upside: -17.48%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $0.30
Upside: -